Fri Apr 11 00:10:00 UTC 2025: **NeuroSense Therapeutics Unveils Promising ALS Treatment Data**

**Cambridge, MA (April 9, 2025) –** NeuroSense Therapeutics (NASDAQ: NRSN) announced groundbreaking findings from its Phase 2b PARADIGM clinical trial for PrimeC, an investigational treatment for amyotrophic lateral sclerosis (ALS). The data, presented at the 77th Annual American Academy of Neurology (AAN) Meeting, revealed significant microRNA (miRNA) modulation in patients treated with PrimeC.

The study showed a 33% reduction in disease progression and a 58% improvement in survival rates compared to the placebo group. This improvement is attributed to the consistent downregulation of 161 miRNAs, including ALS-associated miR-199 and miR-181, in PrimeC-treated patients. These miRNAs are linked to neuroinflammation and mortality risk in ALS.

“These results provide compelling support for PrimeC’s potential to modify disease progression in ALS,” said Alon Ben-Noon, CEO of NeuroSense Therapeutics. “The impact on miRNA expression validates our approach and positions PrimeC as a promising therapeutic candidate.”

The research, conducted in collaboration with Tel Aviv University and Loma Linda University, provides a strong biological mechanism to explain PrimeC’s clinical benefits. This mechanistic understanding, coupled with the robust biomarker data, strengthens the case for advancing PrimeC to Phase 3 trials. The AAN presentation, in a highly selective Late Breaker session, signifies the importance and novelty of these findings.

Read More